Friday, March 11, 2011

Stem Cell Stocks Are Growing

According to the latest Journal of the Congress of Neurological Surgeons Research, Neurosurgery, bone marrow stem cells derived from a patient's own bone marrow were safely used in pediatric patients with severe traumatic brain injury, according to results of a Phase I clinical trial at The University of Texas Health Science Center at Houston.

Research has been continuing into the utilization of stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. just updated its free downloadable list of over ten stem cell stocks. Can one of these provide a cure for your portfolio?

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $8.9 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a PE of 94 and a forward PE of 33.

Cellgene (CELG) is a $24.7 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 28 and a forward PE of 13.

Integra Lifesciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 22 times earnings, and 14.5 times forward earnings.

For a database of over a dozen stem cell stocks which you can download, sort, and update, go to

Disclosure: Author did not own any of the above at the time the article was written.


No comments: